Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 286

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 286
---
-hours per year for all such
support. In consideration for receiving such support, the Company pays Baxter $60 per year until the Company will receive a Food and Drug
Administration (the “FDA”) approval to market GelrinC in the United States. Following FDA approval to market GelrinC in the
United States, the Company shall pay Baxter $200 per year during the term of this Services Agreement; however, the year the Company will
receive an FDA approval to market GelrinC in the United States, the Company must pay the remining $140 balance for that year within 30
days after receiving such approval. The Company incurred expenses under the Services Agreement of $60 in each of the year ended December
31, 2023 and 2022.

| 3. | In July 2008, the Company entered into a Supply Agreement with Baxter and Teva which was amended and restated on January 6, 2009, pursuant to which the Company agreed to purchase Tisseel VHSD fibrin sealant Kit (the “Tisseel”), from Teva, with Teva being Baxter’s exclusive distribution agent in Israel for Tisseel, for manufacture of GelrinC. The Supply Agreement was amended and restated. The Supply Agreement provides for up to 1,000 kits of Tisseel of the 2 ml Tisseel kit, or 500 kits of Tisseel of the 4 ml Tisseel kit, or 200 kits of Tisseel the 10 ml Tisseel kits per year at a fixed purchase price of $0.136 per unit. The payments under the Supply Agreement are due 30 days from the date of invoice and the Company is subject to a service charge of 1% per month on all amounts past due. |

The Supply Agreement had an initial
term of 3 years which ended on April 1, 2011; however, the Supply Agreement has an ever-green clause and is automatically renewable
for consecutive 1 year terms unless either party gives notice of termination at least 3 months prior to the then current term. The
Supply Agreement may be terminated without cause by Baxter upon 90 days’ prior written notice to the other parties. In
addition, either party may terminate the Supply Agreement in the event of an uncured material breach or insolvency.

<div align='center'>F-37</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S.